c albicans laboratory strain sc5314  (ATCC)

Journal: RSC Chemical Biology

Article Title: Prochelators modulate azole activity against Candida albicans in a metal-dependent manner

doi: 10.1039/d6cb00073h

Figure Lengend Snippet: (A) Effect of prochelators (AH1-S) 2 , (IT1-S) 2 , (244mTC-S) 2 , and (TC1-S) 2 on growth of C. albicans strain SC5314. (AH1-S) 2 and (IT1-S) 2 decrease growth at 24 h while (244mTC-S) 2 and (TC1-S) 2 are inactive at the concentrations tested. At 48 h, cells have recovered growth. (B) (AH1-S) 2 and (IT1-S) 2 decrease growth at 24 h of C. albicans Y172, a fluconazole-resistant clinical isolate. Cell growth in SD medium was measured by OD 600 . ( n = 2–5 biological replicates each of n = 1–3 technical replicates). Error bars represent Standard Error of Mean (SEM). Welch ANOVA p -value < 0.0001, Dunnett's T3 multiple comparison p -value = 0.032 (*), 0.0021 (**) or < 0.0001 (****).

Article Snippet: Candida albicans laboratory strain SC5314 (MYA 28776), purchased from ATCC, was used for all experiments unless otherwise noted .

Techniques: Comparison

Journal: RSC Chemical Biology

Article Title: Prochelators modulate azole activity against Candida albicans in a metal-dependent manner

doi: 10.1039/d6cb00073h

Figure Lengend Snippet: Left column (A) (AH1-S) 2 and right column (B) (IT1-S) 2 modulate growth inhibitory effect of azoles against C. albicans SC5314 (SD medium, 48 h, n = 2–4 biological replicates of n = 1–3 technical replicates). Experiments with (AH1-S) 2 were performed with at least one biological replicate under minimal light exposure.

Article Snippet: Candida albicans laboratory strain SC5314 (MYA 28776), purchased from ATCC, was used for all experiments unless otherwise noted .

Techniques:

Journal: RSC Chemical Biology

Article Title: Prochelators modulate azole activity against Candida albicans in a metal-dependent manner

doi: 10.1039/d6cb00073h

Figure Lengend Snippet: (A)–(D) Metals were added into SD medium made without the designated metal to give a concentration that ranged from deficient to excess. Under these conditions, C. albicans SC5314 were not treated (NT, black bars, circles) or treated with 8 µM fluconazole (purple bars, squares), 15 µM (AH1-S) 2 (pink bars, triangles), (IT1-S) 2 (light blue, triangles), or combined 15 µM prochelator plus 8 µM fluconazole (green triangles or dark blue rhombus). Growth was measured by OD 600 after 48 h and normalized relative to non-treated cells. (E) Cidality assays on YPD agar plates after 48 h. Non-toxic levels of copper convert (AH1-S) 2 from fungistatic to fungicidal. The images above are representative of at least n = 2 biological replicates of n = 1–3 technical replicates. Error bars represent SEM.

Article Snippet: Candida albicans laboratory strain SC5314 (MYA 28776), purchased from ATCC, was used for all experiments unless otherwise noted .

Techniques: Concentration Assay

Journal: RSC Chemical Biology

Article Title: Prochelators modulate azole activity against Candida albicans in a metal-dependent manner

doi: 10.1039/d6cb00073h

Figure Lengend Snippet: Levels of (A) iron, (B) manganese, (C) zinc, and (D) copper in C. albicans SC5314 after 90 min and 6 h of treatment with 15 µM (AH1-S) 2 , 10 µM fluconazole, 10 µM copper, or a combination. Data are plotted as fold change relative to the respective metal concentration for non-treated cells (represented by dashed line). Error bars represent SEM; n = 2–3 biological replicates with multiple technical replicates; at least one biological replicate performed under minimal light conditions. Welch's ANOVA p -value = 0.0001, Dunnett's T3 p -value = 0.0438 (*), 0.0075 (**), and 0.0001 (***).

Article Snippet: Candida albicans laboratory strain SC5314 (MYA 28776), purchased from ATCC, was used for all experiments unless otherwise noted .

Techniques: Concentration Assay

Journal: RSC Chemical Biology

Article Title: Prochelators modulate azole activity against Candida albicans in a metal-dependent manner

doi: 10.1039/d6cb00073h

Figure Lengend Snippet: (A) Percent colony forming units (CFUs)/mL of C. albicans SC5314 co-cultured with macrophages relative to the CFU/mL of the non-treated mono-culture. (B) Macrophage cytotoxicity as measured by LDH assay. (C) Images of cells in 96-well plates under co-culture conditions. Left to right: NT, 1.5 µM (AH1-S) 2 , 6.5 µM (AH1-S) 2 , 25 µM (AH1-S) 2 , 2 µM fluconazole, and 2 µM fluconazole + 6.5 µM (AH1-S) 2 . Cells were grown in DMEM under mammalian cell culture conditions. Red arrow – macrophage; blue arrow – C. albicans hyphae.

Article Snippet: Candida albicans laboratory strain SC5314 (MYA 28776), purchased from ATCC, was used for all experiments unless otherwise noted .

Techniques: Cell Culture, Lactate Dehydrogenase Assay, Co-Culture Assay

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Antimicrobial Properties of 8-Hydroxyserrulat-14-en-19-oic Acid for Treatment of Implant-Associated Infections

doi: 10.1128/AAC.01735-12

Figure Lengend Snippet: Microorganism strains used in this study

Article Snippet: CFU were determined by plating of aliquots of 10-fold dilutions of bacterial cultures on Mueller-Hinton agar (MHA), followed by 24 h of incubation at 37°C. table ft1 table-wrap mode="anchored" t5 caption a7 Species Strain a Relevant properties Source or reference Staphylococcus aureus Western Samoan Phage Pattern A (WSPPA) * MRSA ST30 13 ME230 * MSSA, isogenic ΔSCC mec mutant of WSPPA M. Ender b SA113 (ATCC 35556) † MSSA, production of PIA-mediated biofilm under aerobic conditions 14 Staphylococcus epidermidis 1457 ‡ Efficient biofilm producer 17 1457 Δ ica ‡ Isogenic Δ ica mutant, devoid of PIA-mediated biofilm 17 Mycobacterium tuberculosis ATCC 27294 (H37Rv) § Rifampin-sensitive strain 15 ATCC 35838 (H37Rv-RIF-R) ‡ Rifampin-resistant strain Streptococcus pyogenes ATCC 19615 § Laboratory strain isolated from human 16 Streptococcus pneumoniae TIGR4 (JNR.7/87) Encapsulated, virulent strain Enterococcus faecalis ATCC 19433 § Laboratory strain Pseudomonas aeruginosa PA01 ¶ Laboratory strain isolated from human Escherichia coli ATCC 25922 Human clinical isolate Candida albicans SC5314 ∥ Laboratory strain isolated from human Candida glabrata t608919 ‡ Clinical isolate This study Candida krusei ATCC 6258 ‡ Reference laboratory strain isolated from human Open in a separate window a Sources: *, B. Berger-Bächi, Zürich, Switzerland; †, F. Götz, Tübingen, Germany; ‡, D. Mack, Swansea, United Kingdom; §, R. Frei, Basel, Switzerland; ¶, U. Jenal, Basel, Switzerland; ∥, S. Leibundgut-Landmann, Zürich, Switzerland. b M. Ender, ETH Zürich, Switzerland (unpublished data).

Techniques: Western Blot, Mutagenesis, Isolation

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Antimicrobial Properties of 8-Hydroxyserrulat-14-en-19-oic Acid for Treatment of Implant-Associated Infections

doi: 10.1128/AAC.01735-12

Figure Lengend Snippet: In vitro susceptibility of Gram-positive and Gram-negative bacteria and fungi to EN4 determined as MICs and MBCs

Article Snippet: CFU were determined by plating of aliquots of 10-fold dilutions of bacterial cultures on Mueller-Hinton agar (MHA), followed by 24 h of incubation at 37°C. table ft1 table-wrap mode="anchored" t5 caption a7 Species Strain a Relevant properties Source or reference Staphylococcus aureus Western Samoan Phage Pattern A (WSPPA) * MRSA ST30 13 ME230 * MSSA, isogenic ΔSCC mec mutant of WSPPA M. Ender b SA113 (ATCC 35556) † MSSA, production of PIA-mediated biofilm under aerobic conditions 14 Staphylococcus epidermidis 1457 ‡ Efficient biofilm producer 17 1457 Δ ica ‡ Isogenic Δ ica mutant, devoid of PIA-mediated biofilm 17 Mycobacterium tuberculosis ATCC 27294 (H37Rv) § Rifampin-sensitive strain 15 ATCC 35838 (H37Rv-RIF-R) ‡ Rifampin-resistant strain Streptococcus pyogenes ATCC 19615 § Laboratory strain isolated from human 16 Streptococcus pneumoniae TIGR4 (JNR.7/87) Encapsulated, virulent strain Enterococcus faecalis ATCC 19433 § Laboratory strain Pseudomonas aeruginosa PA01 ¶ Laboratory strain isolated from human Escherichia coli ATCC 25922 Human clinical isolate Candida albicans SC5314 ∥ Laboratory strain isolated from human Candida glabrata t608919 ‡ Clinical isolate This study Candida krusei ATCC 6258 ‡ Reference laboratory strain isolated from human Open in a separate window a Sources: *, B. Berger-Bächi, Zürich, Switzerland; †, F. Götz, Tübingen, Germany; ‡, D. Mack, Swansea, United Kingdom; §, R. Frei, Basel, Switzerland; ¶, U. Jenal, Basel, Switzerland; ∥, S. Leibundgut-Landmann, Zürich, Switzerland. b M. Ender, ETH Zürich, Switzerland (unpublished data).

Techniques: In Vitro, Bacteria